We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Let's take a look at 2 charts.
Perrigo hit some bumps, but it offers deep value and dividend growth.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
EBIX offers extensive potential gains while downside appears small.
After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.
As obesity rates climb higher, the quarterly dividend of Medifast should, too.
Mydecine Innovations Group -- formerly known as NewLeaf -- signed an agreement with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.
We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.